LSD for anxiety and psychedelic clinical trials with MindMed CMO, Dr. Daniel Karlin



In today’s episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Dan Karlin. Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He currently serves as the Chief Medical Officer of MindMed, a drug development company striving to deliver on the therapeutic potential of psychedelics to address unmet patient needs in psychiatry, addiction, pain, and neurology. Numinus is a trial site for MindMed’s MM-120 or LSD dose-finding study for the treatment of anxiety symptoms, so they discuss that study and what LSD treatment might look like in a post-approval clinical context. They discuss the challenges of mental health care accessibility and affordability, explore the philosophy behind the psychiatric diagnostic system, talk about the societal burden of anxiety, compare and contrast anxiety vs depression, and much more.

(2:35) Dr. Dan Karlin introduces himself and psychedelic studies
(13:34) The path to psychedelic approval
(16:37) Why anxiety?
(21:42) Why LSD?
(24:51) MM-120 and accessibility
(33:21) The burden of anxiety in society
(50:44) MindMed updates

Would you like to be a guest
on our podcast?

Enter your info and we'll reach out to you asap.


Would you like to be a guest on our podcast?

By signing up you consent to the Privacy Policy & Terms of Use.
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram